trial

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCTId NCT02104752
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 39 (actual)
Sponsored by VA Greater Los Angeles Healthcare System
Primary completion 2016-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
39 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-07
Primary completion
2016-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Curcumin

Sponsors

VA Greater Los Angeles Healthcare SystemLead Sponsor
Stanley Medical Research InstituteCollaborator
Theravalues, Inc.Collaborator
University of California Riverside at C.I. Trials, Inc.-Inland EmpireCollaborator

Investigators

3
Stephen J Heishman, Ph.D.Principal Investigator
Jonathan K Wynn, Ph.D.Principal Investigator
Michael C Davis, M.D., Ph.D.Principal Investigator

Sites

1 total
Los Angeles, United States

Linked catalysts

1
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia — primary completion2016-05

Facts & assertions

4 sourced
Enrollment
39
Phase
PHASE1,PHASE2
Primary Completion Date
2016-05
Status
COMPLETED
relationships
The graph out of here
drug
Curcumin
drug
lead_sponsor
VA Greater Los Angeles Healthcare System
company
collaborator
Stanley Medical Research Institute
company
Theravalues, Inc.
company
indication
Psychosis
indication
Cognition
indication
Psychotic Disorders
indication
investigator
Stephen J Heishman, Ph.D.
person
Jonathan K Wynn, Ph.D.
person
Michael C Davis, M.D., Ph.D.
person